These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 25502629

  • 21. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y, Ma G, Su C, Wu P, Wang H, Song X, Yu Q, Zeng A, Zhou S.
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [Abstract] [Full Text] [Related]

  • 22. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 23. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

  • 24. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT, Yu CJ, Yang JC, Shih JY.
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [Abstract] [Full Text] [Related]

  • 25. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [Abstract] [Full Text] [Related]

  • 26. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
    Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K.
    Clin Cancer Res; 2012 Nov 15; 18(22):6219-26. PubMed ID: 22843788
    [Abstract] [Full Text] [Related]

  • 27. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R.
    Expert Opin Drug Discov; 2013 Sep 15; 8(9):1165-79. PubMed ID: 23805942
    [Abstract] [Full Text] [Related]

  • 28. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.
    Lung Cancer; 2016 Jan 15; 91():70-2. PubMed ID: 26464158
    [Abstract] [Full Text] [Related]

  • 29. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
    Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S.
    Cancer Sci; 2017 Jan 15; 108(1):53-60. PubMed ID: 27783866
    [Abstract] [Full Text] [Related]

  • 30. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM.
    Future Oncol; 2018 Aug 15; 14(18):1875-1882. PubMed ID: 29536761
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Alectinib for advanced ALK-positive non-small-cell lung cancer.
    Ly AC, Olin JL, Smith MB.
    Am J Health Syst Pharm; 2018 Apr 15; 75(8):515-522. PubMed ID: 29467147
    [Abstract] [Full Text] [Related]

  • 33. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM, Noonan S, O'Bryant C, Jimeno A.
    Drugs Today (Barc); 2015 Mar 15; 51(3):161-70. PubMed ID: 25876560
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
    Ou SH, Weitz M, Jalas JR, Kelly DF, Wong V, Azada MC, Quines O, Klempner SJ.
    Lung Cancer; 2016 Jun 15; 96():15-8. PubMed ID: 27133743
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
    Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC.
    J Thorac Oncol; 2014 May 15; 9(5):646-53. PubMed ID: 24722154
    [Abstract] [Full Text] [Related]

  • 39. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH, Mok K, Leung LK, Mok TS.
    Future Oncol; 2015 May 15; 11(5):735-45. PubMed ID: 25757678
    [Abstract] [Full Text] [Related]

  • 40. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Yamazaki S, Lam JL, Zou HY, Wang H, Smeal T, Vicini P.
    Drug Metab Dispos; 2015 Jan 15; 43(1):54-62. PubMed ID: 25349124
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.